UBS has given Schott Pharma AG a "Neutral" rating and set a target price of €32.60 for the company's financial results in the 2023/24 fiscal year.
Analyst Olivier Calvet predicts that Schott Pharma, a manufacturer of specialty glass for the pharmaceutical industry, will see a gradual recovery in its mass business in 2025, which accounts for about half of its sales.
The report, published on November 25, 2024, highlights the expected improvements in Schott Pharma's performance, reflecting broader trends in the pharmaceutical sector.
Investors are advised to closely monitor the upcoming financial figures for further insights into the company's recovery trajectory.